Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins

Molecular Cancer Therapeutics

Volumn 8, Issue 4, 2009, Pages 904-913

  Wei, Jun ^a   Kitada, Shinichi ^a   Rega, Michele F ^a   Emdadi, Aras ^a   Yuan, Hongbin ^a   Cellitti, Jason ^a   Stebbins, John L ^a   Zhai, Dayong ^a   Sun, Jiazhi ^b   Yang, Li ^a   Dahl, Russell ^a   Zhang, Ziming ^a   Wu, Bainan ^a   Wang, Si ^a   Reed, Tyler A ^a   Lawrence, Nicholas ^b   Sebti, Said ^b   Reed, John C ^a   Pellecchia, Maurizio ^a  

^a BURNHAM INSTITUTE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOGOSSYPOL DERIVATIVE; BI 79D1; BI 79D10; BI 79D11; BI 79D12; BI 79D3; BI 79D6; BI 79D8; BI 79D9; BI 79F3; BI 79F5; BI 79F7; GOSSYPOL; GOSSYPOL DERIVATIVE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; UNCLASSIFIED DRUG; APOGOSSYPOL; APOPTOSIS REGULATORY PROTEIN; BAK1 PROTEIN, MOUSE; BAX PROTEIN (53 86); BAX PROTEIN (53-86); BAX PROTEIN, MOUSE; BCL 2 LIKE PROTEIN 11; BCL-2-LIKE PROTEIN 11; DRUG DERIVATIVE; MEMBRANE PROTEIN; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; ONCOPROTEIN; PEPTIDE FRAGMENT; PROTEIN BCL X;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CELL PROTECTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; EMBRYO; FIBROBLAST; FLUORESCENCE POLARIZATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; IN VITRO STUDY; IN VIVO CULTURE; LUNG CANCER; LYMPHOMA; LYMPHOMA CELL LINE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN SYNTHESIS INHIBITION; RAT; SPLEEN; SPLEEN CELL; TRANSGENIC MOUSE; ANIMAL; ARTIFICIAL MEMBRANE; BAGG ALBINO MOUSE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; LIVER MICROSOME; LUNG TUMOR; MALE; METABOLISM; MOUSE MUTANT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PHYSIOLOGY; SYNTHESIS; TUMOR CELL CULTURE;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CELL SURVIVAL; FEMALE; FLUORESCENCE POLARIZATION; GOSSYPOL; HUMANS; LUNG NEOPLASMS; LYMPHOMA; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MEMBRANE PROTEINS; MEMBRANES, ARTIFICIAL; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROSOMES, LIVER; MODELS, MOLECULAR; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; TUMOR CELLS, CULTURED;

EID: 66449119642     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-1050     Document Type: Article

References (30)

1. Vaux DL, Korsmeyer SJ. Cell death in development. Cell 1999;96:245-254 (Pubitemid 29059354)
2. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999;17:2941-2953 (Pubitemid 29415256)
3. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-164 (Pubitemid 34161136)
4. Reed JC. Apoptosis-based therapies. Nat Rev Drug Discov 2002;1:111-121 (Pubitemid 41646518)
5. Reed JC. Molecular biology of chronic lymphocytic leukemia: implications for therapy. Semin Hematol 1998;35:3-13. (Pubitemid 28326232)
6. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science (New York) 1998;281:1322-1326 (Pubitemid 28406819)
7. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999;13:1899-1911 (Pubitemid 29407357)
8. Wang JL, Liu D, Zhang ZJ, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A 2000;97:7124-7129 (Pubitemid 30431428)
9. Degterev A, Lugovskoy A, Cardone M, et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 2001;3:173-182 (Pubitemid 32118371)
10. Reed JC. Bcl-2 family proteins. Oncogene 1998;17:3225-3236 (Pubitemid 29043975)
11. Reed JC. Bcl-2 family proteins: strategies for overcoming chemoresistance in cancer. Adv Pharmacol 1997;41:501-532
12. Kitada S, Leone M, Sareth S, Zhai D, Reed JC, Pellecchia M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem 2003;46:4259-4264 (Pubitemid 37153007)
13. Zhang M, Liu H, Guo R, et al. Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem Pharmacol 2003;66:93-103. (Pubitemid 36724903)
14. Wang G, Nikolovska-Coleska Z, Yang C-Y, et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 2006;49:6139-6142 (Pubitemid 44595187)
15. Wei J, Rega M, Kitada S, et al. Synthesis and evaluation of Apogossypol atropisomers as potential Bcl-xL antagonists. Cancer Lett 2009;273:107-113
16. Shelley MD, Hartley L, Groundwater PW, Fish RG. Structure-activity studies on gossypol in tumor cell lines. Anticancer Drugs 2000;11:209-216 (Pubitemid 30258801)
17. Becattini B, Kitada S, Leone M, et al. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). Chem Biol 2004;11:389-395
18. Kitada S, Kress CL, Krajewska M, Jia L, Pellecchia M, Reed JC. Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). Blood 2008;111:3211-3219
19. Coward L, Gorman G, Noker P, et al. Quantitative determination of apogossypol, a proapoptotic analog of gossypol, in mouse plasma using LC/MS/MS. J Pharm Biomed Anal 2006;42:581-586 (Pubitemid 44636096)
20. Sattler M, Liang H, Nettesheim D, et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science (New York) 1997;275:983-986 (Pubitemid 27087715)
21. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997;267:727-748 (Pubitemid 27170693)
22. Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput Aided Mol Des 1997;11:425-445
23. Teschner M, Henn C, Vollhardt H, Reiling S, Brickmann J. Texture mapping: a new tool for molecular graphics. J Mol Graph 1994;12:98-105. (Pubitemid 24219249)
24. Meltzer PC, Bickford HP, Lambert GJ. A regioselective route to gossypol analogues: the synthesis of gossypol and 5,5′-didesisopropyl-5,5′- diethylgossypol. J Org Chem 1985;50:3121-3124 (Pubitemid 15226006)
25. Ramjaun AR, Tomlinson S, Eddaoudi A, Downward J. Upregulation of two BH3-only proteins, Bmf and Bim, during TGF β-induced apoptosis. Oncogene 2007;26:970-981 (Pubitemid 46272202)
26. Katsumata M, Siegel RM, Louie DC, et al. Differential effects of Bcl-2 on T and B cells in transgenic mice. Proc Natl Acad Sci U S A 1992;89:11376-11380
27. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumors. Nature 2005;435:677-681 (Pubitemid 40825512)
28. Cory S, Adams JM. Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell 2005;8:5-6. (Pubitemid 40991809)
29. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science (New York) 2001;292:727-730 (Pubitemid 32385543)
30. Zhai D, Jin C, Shiau CW, Kitada S, Satterthwait AC, Reed JC. Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther 2008;7:1639-1646